Tonghua Golden-Horse Plans to Acquire Majority Stake in Eight Plus One Pharma to Strengthen Neurological Disease Focus

Stock News08-06

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has announced that its wholly-owned subsidiary, Guilin Golden-Horse Innovation Investment Co., Ltd. (referred to as "Guilin Golden-Horse"), signed a Merger and Acquisition Intent Agreement with Eight Plus One Pharmaceutical Co., Ltd. (referred to as "Eight Plus One") on August 6, 2026.

Under the agreement, Guilin Golden-Horse intends to acquire a controlling stake in Eight Plus One. Eight Plus One is an innovative pharmaceutical enterprise primarily focused on original new drug research and development, headquartered in the Guilin Economic and Technological Development Zone.

The company holds 23 pharmaceutical R&D patents and possesses clinical trial approvals for two Class 1 chemical new drug varieties and one Class 1 traditional Chinese medicine new drug variety. This strategic move is a key step in deepening Tonghua Golden-Horse's presence in the neurological disease sector and accelerating its strategic transformation.

By leveraging Eight Plus One's original new drug research platform and product pipeline, the acquisition aims to further enrich the company's innovative product portfolio in neurology, enhance its overall competitiveness and long-term value in the pharmaceutical innovation field, and drive Tonghua Golden-Horse's complete transformation into a research and innovation-led comprehensive pharmaceutical enterprise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103242279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103242279","market":"other","top_or_hot":-1,"title":"Tonghua Golden-Horse Plans to Acquire Majority Stake in Eight Plus One Pharma to Strengthen Neurological Disease Focus","media":"Stock News","content":"<p>Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (<b>000766.SZ</b>) has announced that its wholly-owned subsidiary, Guilin Golden-Horse Innovation Investment Co., Ltd. (referred to as \"Guilin Golden-Horse\"), signed a <b>Merger and Acquisition Intent Agreement</b> with Eight Plus One Pharmaceutical Co., Ltd. (referred to as \"Eight Plus One\") on August 6, 2026.<br><br>Under the agreement, Guilin Golden-Horse intends to acquire a controlling stake in Eight Plus One. Eight Plus One is an innovative pharmaceutical enterprise primarily focused on original new drug research and development, headquartered in the Guilin Economic and Technological Development Zone.<br><br>The company holds 23 pharmaceutical R&D patents and possesses clinical trial approvals for two Class 1 chemical new drug varieties and one Class 1 traditional Chinese medicine new drug variety. This strategic move is a key step in deepening Tonghua Golden-Horse's presence in the neurological disease sector and accelerating its strategic transformation.<br><br>By leveraging Eight Plus One's original new drug research platform and product pipeline, the acquisition aims to further enrich the company's innovative product portfolio in neurology, enhance its overall competitiveness and long-term value in the pharmaceutical innovation field, and drive Tonghua Golden-Horse's complete transformation into a research and innovation-led comprehensive pharmaceutical enterprise.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonghua Golden-Horse Plans to Acquire Majority Stake in Eight Plus One Pharma to Strengthen Neurological Disease Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonghua Golden-Horse Plans to Acquire Majority Stake in Eight Plus One Pharma to Strengthen Neurological Disease Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-06 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (<b>000766.SZ</b>) has announced that its wholly-owned subsidiary, Guilin Golden-Horse Innovation Investment Co., Ltd. (referred to as \"Guilin Golden-Horse\"), signed a <b>Merger and Acquisition Intent Agreement</b> with Eight Plus One Pharmaceutical Co., Ltd. (referred to as \"Eight Plus One\") on August 6, 2026.<br><br>Under the agreement, Guilin Golden-Horse intends to acquire a controlling stake in Eight Plus One. Eight Plus One is an innovative pharmaceutical enterprise primarily focused on original new drug research and development, headquartered in the Guilin Economic and Technological Development Zone.<br><br>The company holds 23 pharmaceutical R&D patents and possesses clinical trial approvals for two Class 1 chemical new drug varieties and one Class 1 traditional Chinese medicine new drug variety. This strategic move is a key step in deepening Tonghua Golden-Horse's presence in the neurological disease sector and accelerating its strategic transformation.<br><br>By leveraging Eight Plus One's original new drug research platform and product pipeline, the acquisition aims to further enrich the company's innovative product portfolio in neurology, enhance its overall competitiveness and long-term value in the pharmaceutical innovation field, and drive Tonghua Golden-Horse's complete transformation into a research and innovation-led comprehensive pharmaceutical enterprise.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"","article_id":"1103242279","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103242279","pubTimestamp":1786014514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has announced that its wholly-owned subsidiary, Guilin Golden-Horse Innovation Investment Co., Ltd. (referred to as \"Guilin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0077":"质押式回购","000766":"通化金马","BK0239":"医药制造","BK0060":"抗癌"},"translate_title":"通化金马计划收购八加一制药的多数股权，以加强神经系统疾病的重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000766":1},"content_text":"Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has announced that its wholly-owned subsidiary, Guilin Golden-Horse Innovation Investment Co., Ltd. (referred to as \"Guilin Golden-Horse\"), signed a Merger and Acquisition Intent Agreement with Eight Plus One Pharmaceutical Co., Ltd. (referred to as \"Eight Plus One\") on August 6, 2026.Under the agreement, Guilin Golden-Horse intends to acquire a controlling stake in Eight Plus One. Eight Plus One is an innovative pharmaceutical enterprise primarily focused on original new drug research and development, headquartered in the Guilin Economic and Technological Development Zone.The company holds 23 pharmaceutical R&D patents and possesses clinical trial approvals for two Class 1 chemical new drug varieties and one Class 1 traditional Chinese medicine new drug variety. This strategic move is a key step in deepening Tonghua Golden-Horse's presence in the neurological disease sector and accelerating its strategic transformation.By leveraging Eight Plus One's original new drug research platform and product pipeline, the acquisition aims to further enrich the company's innovative product portfolio in neurology, enhance its overall competitiveness and long-term value in the pharmaceutical innovation field, and drive Tonghua Golden-Horse's complete transformation into a research and innovation-led comprehensive pharmaceutical enterprise.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103242279","isCrawlerRequest":true}